Biomarker Driven Drug Development
With drug development facing challenges from ever increasing cost of developing drugs and rise in the failure rate for drugs in phase II and III clinical trials, stratification, toxicity and efficacy of predictive biomarkers are being employed as risk mitigation strategies almost universally by pharmaceutical companies to overcome these challenges. Also, as these same companies move to personalized medicine and companion diagnostics, the need to identify and quantify disease relevant biomarkers in real-world specimens throughout the development process is even more important.
The automated ViBE workstation powered by the robust and flexible AMMP assays is the perfect platform to drive your development program. Whether monitoring and measuring protein biomarkers for drug efficacy studies or clinical trial samples, your protein analysis can all be done on one platform using off the shelf kits and reagents or custom assay components tailored to your specific target. BioScale has application experience in all of the key therapeutic areas of drug development and can enable you to rapidly and cost-effectively develop new biomarker assays tailored to your specific needs
Don’t see your specific application area here? Contact us discuss your biomarker analytical needs with us.
